10 Posts Not to Miss This Week

This week’s highlights in hematology and hemostasis bring together perspectives on global access to bleeding disorder care, advances in hemophilia management, and emerging evidence in thrombosis and transfusion medicine.

From international efforts to strengthen comprehensive hemophilia care in underserved regions to new insights into shared decision-making and treatment selection, these discussions reflect the evolving landscape of bleeding disorder management.

Other notable topics include updated blood safety regulations in Mexico, new perspectives on hemovigilance, the role of heparin in pregnancy complications, and the latest developments in antithrombotic strategies following TAVI.

The roundup also features research opportunities, international conference highlights, journal metrics, and educational resources supporting the global hematology community.

Explore 10 posts featuring this week’s selected discussions, research updates, and perspectives from experts across hematology, thrombosis, and hemostasis.

Rob Maloney, Chief Executive Officer of Hemophilia of Georgia:

”Our mission at Hemophilia of Georgia doesn’t stop at the Georgia state line.

I’m spending time in the Dominican Republic this week with the World Federation of Hemophilia and colleagues committed to improving care for people living with bleeding disorders.

It’s a reminder of how different access to care can look depending on where someone lives. Treatments and comprehensive care that many of us have come to expect in the United States remain difficult to access in other parts of the world.

I’m proud that Hemophilia of Georgia has a longstanding relationship with the bleeding disorders community here.

Working alongside local leaders and organizations like FAHEM, we have an opportunity to share what we’ve learned while supporting their efforts to build stronger, more sustainable systems of care. Especially thankful for Cesar Garrido leadership to keep this mission moving forward…

There is a lot we can learn from one another.

Our mission is More than Medicine. Sometimes that means looking beyond our own borders.”

Marcello Miltersteiner, Hospital Consultant at CSL Vifor:

”Alongside Csl’s team of specialists, participating in the most important congress in hematology (HEMO 2026), was an excellent opportunity to learn, interact with scientific updates, meet great professionals and friends, but above all to reinforce our commitment, as a developer of new technologies, to the evolution of hematology in the care of patients with important needs, such as:

Anemia and iron deficiency, bleeding control and hemophilia.”

Cesar de Almeida Neto, Medical Manager at Hospital Nove de Julho, Head of Apheresis Department at Pró-Sangue Foundation Hemocenter of São Paulo:

”The final day of Hemo 2026 was a great opportunity to discuss different approaches to hemovigilance, including the Spanish model, recent changes in the Brazilian system following the new regulation, and strategies to strengthen hemovigilance practices in transfusion services.

It was also a pleasure to present a poster highlighting the benefits of surgical blood reservation management.

Time to say goodbye to Rio and head home with wonderful memories, great connections, and, above all, valuable knowledge and new ideas to bring back!

Thank you, Hemo 2026! Until next time!”

Saskia Middeldorp, Head and Professor of Internal Medicine at Radboudumc:

”In this commentary in Journal of Thrombosis and Haemostasis on the GROWTH trial, I summarize the lack of evidence, and the evidence of absence of effect, on the use of heparin LMWH for women with pregnancy complications. Thanks to all investigators who remain persistent on getting high-quality evidence that women deserve so much.

It has taken way too long to say goodbye to a promise of heparin that has never been firmly delivered but does harm patients with the burden of injections, costs, and false hope.”

Rhiannon Morris, Senior Research Officer at Walter and Eliza Hall Institute of Medical Research (WEHI):

”Very excited to share that Ive been awarded a travel award from The CASS Foundation to attend the American Society of Hematology annual meeting in Dec 2026!

Grateful for the support and the opportunity to share our latest research , connect with colleagues, and hear about the exciting advances happening across the field.

If you’re heading to ASH this year too, Id love to catch up! Please reach out if you’d like to connect while were there.”

Heiko Tschauner, Partner at Hogan Lovells Cadwalader:

”Mexico has updated its regulatory framework for the disposition of human blood and its components.

The New NOM-253 introduces significant changes for Blood Services, including mandatory NAT testing for HIV and hepatitis B and C, new requirements for Transfusion Medicine Committees, reporting through the SANGRHE platform, and expanded standards for quality control, packaging, and transport.

With the new standard taking effect on April 10, 2027, affected organizations should begin assessing compliance gaps and preparing for implementation.

Read more of the key takeaways.”

Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels:

”More treatment options make shared decision-making in haemophilia both more complex and more essential.

Pleased to share our paper with Quentin Van Thillo and Guy Young:

‘Shared Decision-Making in Haemophilia Involves More Treatment Differentiators in 2026.’

We identify 15 treatment differentiators to help clinicians and patients navigate an expanding therapeutic landscape—from efficacy, safety and treatment burden to monitoring, access and patient-centred outcomes beyond haemostasis.

Designed to complement the World Federation of Hemophilia’s Shared Decision-Making Tool, this framework supports a central goal:

Matching treatment choices to each patient’s needs, preferences and priorities.”

Emmanuel J Favaloro, Editor in Chief of Seminars in Thrombosis and Hemostasis:

”Seminars in Thrombosis and Hemostasis (STH).

2025 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics.

Just published in final form in the last issue of STH for 2026.

Available for free.

Enjoy!”

Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences:

”I’m pleased to share the November 2026 issue (Issue 2) of ‘Tazehnameh’, the monthly bulletin of the Iranian Comprehensive Hemophilia Care Center (ICHCC), co owned by ICHCC and the Blood Diseases Research Center.

Published in Persian in the first week of each month, ‘Tazehnameh’ now also has an English mobile edition.

The PDF is attached. This issue covers news published from 23 September to 22 October 2026, drawn from peer reviewed articles and official announcements, rewritten in plain language and supported by numbered references.

Highlights include:

FDA review of denecimig (Mim8), extended because of manufacturing site remediation, not clinical data
Swiss consensus on desmopressin, recommending a trial before therapeutic use
Launch of the WFH Treatment Guidelines Resource Hub
New US ICD 10 CM code D69.11 for Glanzmann thrombasthenia, relevant to Iran, where Glanzmann is more common due to consanguinity
Two high titer inhibitor cases after AAV gene therapy (ASC618), reported in Blood
World Thrombosis Day 2026’s focus on women’s health, and two ‘How I’ papers in Blood on women and girls with bleeding disorders
The dossier, ‘Novel hemophilia therapies surgical and safety considerations,’ covers emicizumab in special situations, including Canadian registry data (n equal 710; mean ABR 1.00 to 0.47); rebalancing agents (fitusiran, concizumab, marstacimab) in surgery; 15 year EUHASS thrombosis baseline rates; and a patient checklist for before surgery or dental work.

Evidence on surgery, trauma and acute illness with these therapies remains limited.

Decisions should be made with the treatment center.”

Farzin Beygui, Professor of Cardiology at University of Caen Normandy:

”Proud to share the publication of the SOLOTAVI randomized trial design.

The study is assessing aspirin discontinuation at 90 days versus standard long term therapy after TAVI in patients with no ‘other’ indication for aspirin.

Congratulations and many thanks to the study investigators and co-authors of the 23 french centers, for their commitment and major envolvement that has already led to the recruitment of nearly half of the expected 1400.

Looking forward to sharing the results.”

Stay updated with Hemostasis Today.